


 Cite this: *RSC Adv.*, 2022, 12, 8211

Recent trends and advances in polyindole-based nanocomposites as potential antimicrobial agents: a mini review

 Hareesh Pradeep,^a Bindu M.,^b Shwetha Suresh,^b Anjitha Thadathil^a and Pradeepan Periyat ^{*b}

Infections caused by multi-drug resistant microbes are a big challenge to the medical field and it necessitates the need for new biomedical agents that can act as potential candidates against these pathogens. Several polyindole based nanocomposites were found to exhibit the ability to release reactive oxygen species (ROS) and hence they show excellent antimicrobial properties. The features of polyindole can be fine-tuned to make them potential alternatives to antibiotics and antifungal medicines. This review clearly portrays the antimicrobial properties of polyindole based nanocomposites, reported so far for biomedical applications. This review will give a clear insight into the scope and possibilities for further research on the biomedical applications of polyindole based nanocomposites.

 Received 24th December 2021
 Accepted 23rd February 2022

DOI: 10.1039/d1ra09317g

rsc.li/rsc-advances

1. Introduction

Microorganism induced resistance, based on the built-in abilities to nullify the activity of current antibiotics has been considered very crucial in regards to public health, especially in a scenario of the alarming increase in untreatable bacterial infections and scarcity in the production of new antibiotics.^{1–3} One alternative to address the impact of this issue is prevention, *i.e.*, hampering the growth and development or simply preventing their adhesion.^{4–6} In this regard, the development of novel antibacterial materials to avoid the usage of antibiotics becomes an excellent approach. The replacement of conventional antibiotics by nanocomposites presents important advantages to deactivate new strategies of intrinsic resistance developed by multidrug- or even pan-drug-resistant microorganisms.^{7,8}

The exciting properties of nanotechnology have led to the development of antimicrobial nanomaterials in recent years. Nanomaterials can be used as an alternative to antibiotics, because of the ease in fine tuning of their properties such as particle size, crystal defect and morphology.⁹ Understanding the mechanism of antibacterial activity of nanomaterials is important in controlling the *in vivo* dosage.¹⁰ The ability of the material to produce reactive oxygen species (ROS) is of precise attention in regards to toxicity, owing to the oxidation of various cellular constituents by oxygen centered reactive species. ROS may comprise superoxide anions ($O_2^{\cdot-}$), hydroxyl radicals (OH^{\cdot}), singlet oxygen and secondary oxygen centered species

such as H_2O_2 (formed by the disproportionation of $O_2^{\cdot-}$) which then converted to OH^{\cdot} and singlet oxygen.^{11–13} Excellent literature reports are available based on the antibacterial activity of nano ZnO, TiO_2 , MgO, CuO, ZnO/ TiO_2 hybrids and Ag_3PO_4 .^{14–18} It has been shown that, the ROS generated by nanomaterials can be used to treat cancer cells^{11,19–21} and ROS generation strongly depends upon the shape, size, surface area, charge and heterostructure of the nanomaterials.

Fig. 1(A) represents the influence of metallic and metallic oxide nanoparticles on the living systems and Fig. 1(B) represents the factors influencing the nanomaterials induced ROS generation. As the size of the materials becomes nano dimensions, there may be structural defects, owing to which alteration in the surface properties occurs. Electron donor or acceptor, then reacts with oxygen, leading to the formation of superoxide anions ($O_2^{\cdot-}$), which further undergoes Fenton type reactions^{22–24} to generate additional ROS. According to Fenton mechanism, the metal or metallic oxide nanoparticles react with H_2O_2 to form OH^{\cdot} and oxidized metal ion. There is one more mechanism, *i.e.* Haber Weiss mechanism, in which generation of OH^{\cdot} *via* the reaction between H_2O_2 and oxidized metal ions.^{25–28}

Fig. 2 shows a schematic representation of the mechanism of nanoparticle induced ROS generation. Various steps involved are: (1) endocytosis (2) generation of endocytotic vesicles (3) release of nanoparticles from vesicles into the cell. The nanoparticle may then interact with mitochondria and NADPH oxidase, leading to the formation of ROS, owing to which DNA damage, cell cycle termination and alteration in apoptosis occurs.²⁹

It has been reported that H_2O_2 can induce oxidative stress on living cells by forming ROS intracellularly.^{30,31} The intracellular

^aDepartment of Chemistry, University of Calicut, Kerala, India-673635

^bDepartment of Environmental Studies, Kannur University, Kerala, India. E-mail: pperiyat@uoc.ac.in; pperiyat@kannuruniv.ac.in





Fig. 1 (A) Influence of metallic and metallic oxide nanoparticles on the living systems and (B) major factors involved in the nanomaterials induced ROS generation.

ROS formation may happen either by some metabolic process (endogenous) or by other entities such as nanoparticles (exogenous).^{32–34} The ROS facilitated antibacterial activity has been found to be pro-inflammatory.^{35–37} Investigation of the antioxidant features of nanomaterials towards macrophages is of particular attention, owing to the fact that macrophage targeting may be employed to deliver anti-inflammatory drugs at the site of inflammation.

It has been reported that the inflammation (swelling at a particular area, pain and redness due to some injury or infection) is enhanced by some mechanism including ROS generation in macrophages.^{38,39} Studies reveal that the size of nanoparticles plays a crucial role in their uptake by macrophages.⁴⁰ Materials which exhibit both antibacterial and anti-inflammatory properties simultaneously have potential for a variety of biomedical applications.^{41–45}





Fig. 2 A schematic representation of mechanism of nanoparticle induced ROS generation. Reprinted with permission from ref. 29; copyright © MDPI.





Scheme 1 Different pathways of antibacterial activity.

Photodynamic therapy (PDT) is a method of bacterial inactivation through oxidative stress by photosensitization. The photosensitizer absorbs specific wavelength of light, usually from laser sources, followed by visible light irradiation generates ROS.^{46,47} Uncontrolled formation of ROS leading to cell damage and cell death. The photosensitizer is either put into the blood stream *via* veins or applied directly on skin. After a certain period of time, drug is absorbed by the harmful cells. Upon irradiation to the area to be treated, the drug reacts and kills the cells. The time gap between the drug is given and light irradiation is known as drug to light interval.⁴⁸

As a replacement of PDT by photothermal therapy (PTT), also requires photosensitizer which converts light energy into heat, owing to which cell impairment occurs. Generation of heat leads to aggregation and denaturation of the proteins, causes cell death. Here, the irradiation is done by near IR light.^{49,50} Scheme 1 shows different mechanistic pathway of antibacterial activity.

Nowadays, polymer nanocomposites have extensively been employed for antibacterial, tissue engineering, cancer therapy, medical imaging, drug delivery and dental applications. Polymer nanocomposites consist of a macromolecular matrix, in

Table 1 Commonly employed polymer nanocomposites as antimicrobial medicine^a

Polymer nanocomposites	Compositions	Species	CFU mL ⁻¹	Antibacterial activity performances	Biocompatibility tests	Ref.
Chitosan/GO/iron oxide	0.1 wt% GO/iron oxide	<i>S. aureus</i> (Gram positive)	1×10^5	DIZ ~15 mm	Causing concentration dependent hemolysis of human red blood cells	63
Chitosan/GO/ZnO	NG	<i>E. coli</i> (Gram negative)	1×10^6	DIZ ~15 mm	—	64
Chitosan/GO/TiO ₂	Chitosan : GO : TiO ₂ (1 : 20 : 4)	<i>S. aureus</i>	1×10^6	MIC: 0.1 $\mu\text{g mL}^{-1}$	—	64
		<i>E. coli</i>	1×10^6	MIC: 0.1 $\mu\text{g mL}^{-1}$	—	64
		<i>B. subtilis</i> (Gram positive)	1×10^8	With 40 $\mu\text{g mL}^{-1}$ of the material, the OD ₆₀₀ of <i>B. subtilis</i> drop from 0.79 to 0.33 for 12 h	Not causing cytotoxicity against mammalian somatic cells and plant cells	65
				No obvious (24 h)	—	66
PVA/GO	0.1 wt% GO	<i>S. aureus</i>	2×10^5			66
		<i>E. coli</i>	2×10^4			66
PVA/GO/AgNPs	0.01 wt% GO, 10 wt% PVA, 3.9 mM AgNO ₃	<i>S. aureus</i>	1×10^6	BR: 100% (3 h)	—	67
		<i>E. coli</i>	1×10^6	BR: 100% (3 h)	—	67
PLA/GO-ZnO	0.2 wt% GO-ZnO	<i>S. aureus</i>	—	BR: 83% (24 h no light), 99% (24 h with light)	—	68
		<i>E. coli</i>	—	BR: 52% (24 h no light), 98% (24 h with light)	—	68
PAM/rGO/Ag	1 wt% PAM/rGO	<i>S. aureus</i>	—	DIZ: 47 mm	—	69
		<i>Pseudomonas</i> (Gram negative)	—	DIZ: 45 mm	—	69

^a BR: bactericidal rate, DIZ: diameter of inhibitory zone, MIC: minimum inhibitory concentration, CFU: colony forming units.

which nano fillers are embedded. Polymers are excellent hosting materials to fabricate composites, because of the easiness in tailoring their characteristics, to obtain a system, having good processability and durability. Addition of nanofillers to such matrices generates a material, with desired and fine-tuned properties than their counterparts.^{50–55} Poly lactide, polyglycolide and polycaprolactone are biodegradable and biocompatible polymers.^{56–58} Polymer nanocomposites, based on chitosan, poly(*N*-vinyl-2-pyrrolidone) (PVP), polyvinyl alcohol (PVA) and polyvinyl chloride (PVC) have been investigated for antimicrobial properties' evaluation and Table 1 lists a concise literature report of some commonly employed polymer nanocomposites as antimicrobial medicine.

2. Conducting polymer nanocomposites as biomedical agents

Conducting polymers (CPs) are a specific category of synthetic polymers with exceptional electrical and optical characteristics, which involve conjugated chains with alternating single and double bonds.^{59,60} Polyacetylene (PA), polythiophene (PT), poly[3,4-(ethylenedioxy)thiophene] (PEDOT), polypyrrole (PPy), polyindole (PIN), polyphenylene and polyaniline (PANI) are some examples of the most extensively used CPs in biomedical area.⁶¹ CPs have demonstrated promising candidates for numerous biomedical applications due to their biocompatibility, gifted response to electrical fields, high electrical conductivity, low-toxicity, good environmental stability, and nanostructured morphology.⁶² Recently, conducting polymers are widely used as antimicrobial and antifungal agents in various sectors such as bio-medical field, food industry, coating industry *etc.* The tendency for CPs to have low processability and not to be degradable, which can potentially be overcome by the synthesis of degradable CPs that are solution processable, and fabrication of CP blends and nanocomposites with various (bio) polymers and nanomaterials, respectively. Table 2 give a complete

literature analysis of conducting polymer nanocomposite materials reported so far as antimicrobial medicine.

2.1. Polyindole (PIN)

Owing to the unique physical and electrochemical properties, polyindole (PIN) has gained marvellous consideration of the researchers, in the past couple of years. They belong to the fused ring compound family, which possesses a benzene and a pyrrole ring; so polyindole have the features of poly(*para*-phenylene) and polypyrrole⁷⁶ as well. Several studies on polyindole revealed that they could be used as promising candidates for applications such as supercapacitors, batteries, electrochromic devices, sensors, electrocatalysis, catalysis, and anticorrosion.^{77–83} Graphene and silver nanoparticles loaded polyindole have been subjected to electro activity studies and found that such system can be used as an electrode material for various applications.⁸⁴

In the early 1976, initial studies have begun on the development of chemical polymerization methods to synthesize polyindole from indole.⁸⁵ In 1982, Tourillon and Garnier synthesized conducting polyindole by employing electrochemical methods.⁸⁶ Compared to polyaniline and polypyrrole, polyindole exhibit high thermal stability (crucial for sterilization, *e.g.*; in an autoclave), excellent oxidation–reduction activity (redox activity), chargeable electrical conductivity, slow rate of degradation and good blending properties.⁸⁷ Because of its exceptional advantages in various domains, many scientists have done healthy research on polyindole and their derivatives in terms of their synthesis, properties, structure and applications. Two strategies have been employed for the synthesis PIN from indole monomers, chemical oxidative polymerization and electrochemical polymerization.⁸⁸ We can precisely control the morphology of PIN formed such as nanowires, nanorods, nano- and micro-fibers, nano- and micro-spheres, and nanobelts.⁷⁸ The chemical oxidative polymerization technique has been employed for the large scale production of PIN.⁸⁹ The mechanism involves the formation of radical cations, by the oxidation

Table 2 Conducting polymer nanocomposite materials as antimicrobial medicine^a

Conducting nanocomposites	Species	CFU mL ⁻¹	Antibacterial activity performances	Biocompatibility tests	Ref.
PPy-Pd	<i>S. aureus</i> (Gram positive)	—	MIC: 5.78 mg mL ⁻¹ MBC: 23.12 mg mL ⁻¹	—	70
PPY-Zn@CuO	<i>E. coli</i> (Gram negative)	—	MIC: 0.078 mg mL ⁻¹	PPY-Zn@CuO pertaining to minimal cytotoxicity	71
PANI-Zn@CuO	<i>S. aureus</i>	—	MIC: 0.156 mg mL ⁻¹		
	<i>E. coli</i>	—	MIC: 0.144 mg mL ⁻¹	PANI-Zn@CuO and PPY-Zn@CuO pertaining to minimal cytotoxicity	71
PPy-NT Ag-NP	<i>S. aureus</i>	—	MIC: 0.144 mg mL ⁻¹		
	<i>E. coli</i>	—	MIC: 0.078 mg mL ⁻¹	—	72
	<i>S. aureus</i>	—	MIC: 0.15625 mg mL ⁻¹		
polyaniline/Pt-Pd	<i>Staphylococcus</i> sp (Gram positive)	—	MIC: 25 mg mL ⁻¹ MBC: 150 mg mL ⁻¹	—	73
AuNP-PTh	<i>E. coli</i> MTCC 433	1 × 10 ⁶	MBC: 112 μM	No harmful influence of AuNP-PTh	74
	<i>L. monocytogenes</i> Scott A (Gram positive)	1 × 10 ⁶	MBC: 112 μM	treatment for various time periods (24 and 48 h)	
Cu-PANI	<i>E. coli</i>	1 × 10 ⁶	—	—	75
	<i>S. aureus</i>	1 × 10 ⁶			

^a MBC: minimum bactericidal concentration.






Fig. 3 Mechanism of chemical polymerization of PIN. Reprinted with permission from ref. 88; copyright ©Elsevier.

of indole monomer and these indole radical cations couple together at 2 and 3 position. The deprotonation of the coupled species results in the formation of a dimer, which again undergoes oxidation, coupling and deprotonation, results in the formation of a trimer and the chain propagates to form the final product as polyindole. The mechanism has been depicted as Fig. 3.

Unlike the chemical polymerization methods, electropolymerization produces PIN directly on a target electrode substrate in a three electrode system. A binder-free electrode has been achieved by using an organic or non-organic electrolyte and dopant material.⁸⁹ Mechanism of the electrochemical polymerization of PIN has been shown as Fig. 4. The coupling position of indole moieties during the polymerisation strongly depends upon the nature of the solution and electrolyte used.⁹⁰

Polyindole based nanocomposites exhibit outstanding antimicrobial properties because of its promising capability to




Fig. 4 Electrochemical polymerization mechanism of PIN formation. Reprinted with permission from ref. 88; copyright © Elsevier.

generate ROS, it can effectively inhibit microbial growth. Although many metal and metal oxide nanoparticles offer excellent antimicrobial activity, their cytotoxicity and safety concerns still exist as a challenge.⁹¹ Polyindole based nanocomposites have been found to exhibit enhanced antimicrobial activity than its partners due to the mutual synergistic enhancement of their properties.⁹² Also, they have less cytotoxic effects on human bodies. Hence, polyindole nanocomposites can be substituted as a potential alternative for antibiotics and can act as an effective biomedical agent.

2.2. Antimicrobial features of polyindole based nanocomposites

The oxidative polymerization of indole moieties produces positive charges at fixed intervals of monomers, along the polymeric chain of polyindole. This cationic nature is responsible for the antibacterial activity of the resulting PIN. The positive charge of polyindole chains electrostatically interacts with the negatively charged surfaces of bacterial cell wall, irreversibly interrupting the membrane structure of the bacteria, leading to penetration through the cells, and efficiently hindering the protein activity.⁸⁷ Owing to the interaction with the charged surfaces and the diffusion of reactive species into the cell wall, cell death occurs by the leakage of vital components from the cells. A schematic representation of the electrostatic interactions and the step of cell death has been shown as Fig. 5.

The incorporation of nanomaterial into polyindole matrices enhance the performance against bacterial growth,




Fig. 5 Schematic representation of electrostatic interactions involved in the mechanism of antibacterial activity of polyindole nanocomposites.



proliferation, and the following cell death owing to the synergistic interaction of the components. With this goal, the polyindole has been combined with different fillers such as Ag, Ag-CuO, Ag-ZnO, Ag/CeO₂, Ag/Co₃O₄, graphene, ZrO₂, TiO₂, and NiO/ZnO nanoparticles. In the following section, strategies for the optimization of polyindole-based nanocomposites as antibacterial agents have been discussed.

2.2.1. Polyindole/Ag based nanocomposites. Ag nanoparticles constitute a class of biologically important metallic nano particles, which can be employed as an antimicrobial agent.⁹³ It has been reported that, the incorporation of Ag nanoparticles into polymeric matrices, impart antimicrobial properties to the latter or enhance it.⁹⁴ By combining the advantages of both the partners *i.e.*, Ag nanoparticles and the polymers, such as strong antimicrobial effect of nano Ag, unique features of polymers such as exceptional structural consistency, various morphologies and architecture and varying chemical compositions, leads to the development of a composite systems with improved properties.^{95–97}

The antimicrobial activity of Ag and its ionic form is due to the binding of metallic ions to certain bio-macromolecular components. It has been reported that the cationic Ag targets binds to negatively charged components of the proteins and nucleic acid, leads to structural deformations in cell membrane and nucleic acids.^{98–100} Ag ions can also interact with electron rich functional groups such as thiols, hydroxyls, imidazoles, phosphates, indoles and amines.¹⁰⁰ The binding of Ag ions to DNA, block transcription whereas those binds to cell surface inhibits bacterial respiration and ATP (adenosine triphosphate) synthesis and Ag ions have the potential to block the respiratory chain of microorganism in the cytochrome oxidase and NADH-succinate dehydrogenase region.¹⁰ Various mechanisms have been suggested to describe the antimicrobial activity of Ag nanoparticles. They are (1) slow release of Ag ions followed by suppression of ATP production and replication of DNA (2) cell membrane damaging directly (3) Production of ROS.¹⁰¹ Electron spin resonance (ESR) studies have been used to confirm the ROS generation.

Many polyindole derivatives have been prepared till now, in regards to the antimicrobial activity of indole monomer, some them shows fungicidal activity. In an interesting work, 1-allylindole-3 carbaldehyde (AIC) was used as the monomer and polymerization was carried out by atom transfer radical polymerization (ATRP) strategy, to form a polyindole derivative.⁹² The synthesis strategy has been depicted as Fig. 6.




Fig. 6 Synthesis strategy of poly(1-allylindole-3 carbaldehyde). Reprinted with permission from ref. 92; copyright © Wiley.

Ag nanoparticles were prepared by using solutions of AgNO₃ and NaBH₄ as precursors. Addition of AgNO₃ to NaBH₄, causes the reduction of AgNO₃ to Ag nanoparticles. A thin layer of borohydride anion got absorbed on the surface of nanoparticles, prevents their agglomeration. Ag nanoparticles synthesized were then introduced into the polymer matrix by ultrasonic-assisted method.⁹³

Antibacterial studies were carried out against human pathogenic bacteria, by two different methods, disc diffusion method and broth dilution method.¹⁰² The results obtained from both the methods were similar, and observed that the monomer AIC doesn't exhibit any antibacterial properties at all, but the polymer PAIC [poly(1-allylindole-3 carbaldehyde) and the nanocomposite (PAICN) does. Table 3 shows the response of different systems towards pathogens.

The association of aldehyde group of PAIC with unprotonated amines on the outer layer of bacterial cells is responsible for its antibacterial activity.¹⁰³ An insignificant activity has been observed against *S. aureus* and *E. faecalis*. They exist as mucoid strains and their cells are being enclosed by a slime coating. The non-mucoid strains are affected more quickly compared to mucoid strains. PAICN shows activity against *E. faecalis*, with a minimum inhibitory concentration of 35 µg mL⁻¹, owing to the slow release of Ag nanoparticles from the matrix. But, no activity was observed against *S. aureus*, *P. mirabilis* and *K. pneumoniae*, since the aldehyde group can't bind with amino acids on the cell surface, they are being participated in stabilizing Ag nanoparticles, owing to the affinity of oxygen atom towards metals.¹⁰⁴

Antimicrobial features of ZnO nanoparticles are well known, which makes them suitable for agriculture and anticancer treatment.^{105–109} Oxidative stress mechanism involving ZnO nanoparticles against *E. coli*, have been well reported.¹⁰² For bulk ZnO, external generation of H₂O₂, is the reason for antibacterial activity. Being amphoteric, ZnO reacts with both acidic and alkaline medium, to generate Zn²⁺ ions. The free Zn²⁺ ions

Table 3 The response of AIC, PAIC and PAICN towards pathogens. Reprinted with permission from ref. 92; copyright © Wiley^a

Sample	Gram positive bacteria		Gram negative bacteria		
	<i>E. faecalis</i>	<i>S. aureus</i>	<i>E. coli</i>	<i>P. mirabilis</i>	<i>K. pneumoniae</i>
Disc diffusion data					
AIC	—	—	—	—	—
PAIC	—	+	—	++	+++
PAICN	++	—	—	—	+
Minimum inhibitory concentration (MIC, in µg mL⁻¹) against pathogens, determined after one day of incubation					
AIC	—	—	—	—	—
PAIC	—	>50	—	50	40
PAICN	35	—	—	—	>50

^a —, no antibacterial activity; +, less than 7 mm; ++, 8–15 mm; +++, more than 15 mm.



Table 4 Average inhibition zone for polyindole/Ag–ZnO nanocomposites, nano ZnO, nano Ag and polyindole (in mm). Reprinted with permission from ref. 110; copyright © Elsevier

Microbes	Gram staining	ZA1	ZA2	ZA3	ZA4	ZA5	ZnO	Ag	Pin
<i>E. coli</i>	Gram negative	18	17	16	18	17	5	7	5
<i>P. mirabilis</i>		13	13	13	13	13	4	8	—
<i>E. faecalis</i>	Gram positive	16	14	13	14	13	6	16	4
<i>B. subtilis</i>		23	20	20	20	20	4	11	—
<i>S. epidermidis</i>		12	11	11	13	13	4	7	5
<i>S. aureus</i>		15	13	12	12	13	3	12	4

may then combine with proteins and carbohydrates, ceases the vital functions of bacteria.¹⁰⁸

In view of the biological characteristics of ZnO nanoparticles, researchers are involved in the fabrication of hybrid materials, in combination with Ag nanoparticles, to achieve excellent antibacterial properties. Ag–ZnO nanocomposites can be used as an effective antimicrobial agent against a number of pathogenic bacteria. A recent study assessed the bactericidal effect of Ag–ZnO nanocomposites with *S. aureus* (Gram-positive) and GFP (green fluorescent protein, Gram-negative recombinant) expressing antibiotic resistant *E. coli*.¹⁰⁹ By introducing these metal nanocomposites on a polymer matrix, its durability can be improved as well as the cytotoxic effects can be minimized.

In an interesting work, polyindole/Ag–ZnO nanocomposites were synthesized *via* chemical oxidation and co-precipitation methods and their antibacterial activities were explored.¹¹⁰ The antibacterial efficiency was assessed in terms of concentration of both AgNO₃ and polyindole. Formation of the nanocomposites have been confirmed by using XRD, FTIR, SEM-EDAX and TEM. The selected bacterial strains for this study were *E. coli*, *P. mirabilis*, *E. faecalis*, *B. subtilis*, *S. epidermidis*, and *S. aureus*. The order of increasing bactericidal efficiency in terms of inhibition zone against the microbes follows the order, *B. subtilis* > *E. coli* > *E. faecalis* > *S. aureus* > *P. mirabilis* > *S. epidermidis*. The data of average zones of inhibition have been presented in Table 4.

It has been shown that the polyindole/Ag–ZnO nanocomposites possess good bactericidal efficiency than their constituents. However, the concentration of AgNO₃ did not play any crucial role in enhancing the overall antibacterial effect. When the nanoparticles are incorporated into the polymer matrix, their exposure gets restricted, leading to a reduction in the cytotoxic effects towards healthy mammalian cells. Hence, the use of polyindole/Ag–ZnO nanocomposites promote a biocompatible, non-cytotoxic and thereby a safe approach in treating bacterial infections.

Elemental Cu and its compounds have been identified as antimicrobial agents by US environmental protection agency (EPA).¹¹¹ Both Cu (+1) and Cu (+2) oxides in the nano-dimension exhibit excellent antimicrobial characteristics against many pathogens. The antimicrobial properties strongly depend upon their particle size, morphology and dissolution of copper ions in different media. The redox cycling between Cu⁺ and Cu²⁺ generates superoxide species, causes the degradation of biomolecules.¹¹²

Ag/CuO nanocomposites have been subjected to antimicrobial activity evaluation against Gram positive microbe *Streptococcus pneumoniae*.¹¹³ High surface-volume ratio of the nanoparticles makes their contact with the microbial cell surfaces, leading to cease the cellular functions.

Polyindole/Ag–CuO systems have been developed *via* a reflux strategy and their antimicrobial efficiency were assessed by well diffusion method.¹¹⁴ While preparing the nanocomposites, the concentration of both polyindole and AgNO₃ has been varied and those of CuO kept constant. The structural characterisations of the prepared nanocomposites were done by FTIR, XRD and SEM analysis. The selected bacterial strains for this study were *E. coli*, *P. mirabilis*, *E. faecalis*, *B. subtilis*, *S. epidermidis*, and *S. aureus*. The antibacterial activity has been compared with the standard ciprofloxacin.⁷³ Fig. 7 represent the antibacterial responses of polyindole/Ag–CuO systems against the pathogens.

It has been observed that the polyindole/Ag–CuO nanocomposites exhibit ~50% activity in comparison with the reference antibiotic, against the pathogen. The antibacterial activity of the nanocomposites has been compared and shown as Fig. 8. The inhibition zone diameter found with nano CuO, Ag and polyindole were 6, 11 and 5 mm respectively. But for polyindole/Ag–CuO nanocomposites, an average zone diameter of 12 mm has been observed.

Since the nanocomposites can easily interact with the bacterial cell wall, the released nanoparticles can effectively penetrate into the bacterial cell causing toxicity to the cells.⁹⁹ Electrostatic interaction between the nanocomposites and cell wall of bacteria eventually leads to cell death.¹¹⁵ The results unveil the possibilities of exploring polyindole/Ag–CuO nanocomposites as an effective antimicrobial agent against pathogenic bacteria.

Cerium and cerium oxide-based nanomaterials have gained considerable attention as effective antibacterial agent against many pathogens, owing to the ROS induced by reversible conversion of oxidation state between Ce (+3) and Ce (+4).¹¹⁶ Literature reports are available based on the incorporation of Ce and CeO₂ into many polymeric matrices for antibacterial applications.^{117,118}

The antibacterial properties of Ag/CeO₂ nanocomposites were comprehensively discussed in a recent article.¹¹⁹ The antibacterial activity of the nanocomposites has been assessed against *S. aureus* and *P. aeruginosa*, Gram-positive and Gram-negative bacteria respectively. For both the bacterial strains, the MIC upon treatment of Ag/CeO₂ nanocomposites were observed to be 3.125 μg mL⁻¹ and 6.25 μg mL⁻¹ respectively.






Fig. 7 Antibacterial response of polyindole/Ag–CuO systems and its constituents against different bacterial strains. Reprinted with permission from ref. 114; copyright © Taylor and Francis Ltd.




Fig. 8 A Comparison of antibacterial activity of polyindole/Ag–CuO systems. Reprinted with permission from ref. 114; copyright © Taylor and Francis Ltd.

Polyindole based Ag doped CeO_2 nanocomposites were explored for its antibacterial properties.¹²⁰ Amorphous nature of the nanocomposites has been confirmed from the XRD results.

The porous polyindole, spherical Ag and CeO_2 nanoparticles were identified from the SEM and TEM investigations. Polyindole/Ag– CeO_2 systems exhibited better antibacterial properties than their constituents. The average zone of inhibition against various bacterial strains have been presented as Table 5.

It has been shown that there is a direct relation between the AgNO_3 concentration and antibacterial properties of the synthesized nanocomposites. As the Ag content increases, the antibacterial property also increases. Smaller size of the nanoparticles makes more impact of toxicity on the bacteria, due to the greater extent of adsorption at the surface.¹²¹

The antifungal activity evaluation of the systems was carried out by agar well diffusion method against the pathogenic fungal species such as *Aspergillus fumigatus*, *Aspergillus flavus*, *Aspergillus niger*, *Candida albicans*, *Aspergillus terreus*, and *Candida tropicalis*. Fig. 9 shows the zone of inhibition against the selected pathogens.

It has been observed that, the polyindole does not exhibit any activity against the selected fungi. Also, the anti-fungal activity does not increase in the presence of Ag nanoparticles. The nanocomposites exhibit moderate antibacterial and minimum antifungal activities against the selected pathogens.

While comparing the antibacterial activity of the nanocomposites with its constituents, it has been found that the

Table 5 Inhibition zone (average, in mm) of nano Ag, nano CeO_2 , polyindole and polyindole/Ag– CeO_2 nanocomposites. Reprinted with permission from ref. 120; copyright © Elsevier

S. no.	Bacteria	Gram staining	Nano CeO_2	Nano Ag	Polyindole	Nanocomposites		
						CM1	CM2	CM3
1	<i>B. subtilis</i>	Gram positive	8.1	7.2	6.3	10.1	12.2	14.3
2	<i>S. aureus</i>		9.2	6.3	8.2	10.3	8.2	9.1
3	<i>S. pneumoniae</i>		4.2	6.2	2.3	7.2	8.3	10.2
4	<i>E. coli</i>	Gram negative	2.3	7.3	8.3	14.2	12.1	11.3
5	<i>P. vulgaris</i>		8.2	6.3	4.2	7.3	8.2	10.2
6	<i>K. pneumoniae</i>		12.2	6.2	10.3	10.2	9.3	10.1






Fig. 9 Antifungal response of polyindole/Ag-CeO₂ systems and individual constituents against (a) *A. fumigates*, (b) *A. flavus*, (c) *A. niger*, (d) *C. albicans*, (e) *A. terreus* and (f) *C. tropicalis*. Reprinted with permission from ref. 120; copyright © Elsevier.

nanocomposites exhibited better antibacterial response against the pathogens. The same trend was observed for antifungal activity as well. This might be due to the synergistic enhancement in properties of the partners. From the above results, the polyindole/Ag-CeO₂ nanocomposite proved to be an efficient antimicrobial agent.

Cobalt oxide nanoparticles are found to be well known antibacterial agent.¹²² In an interesting article, Ag nanoparticles, Co₃O₄ nanoparticles and Ag/Co₃O₄ nanocomposites of different weight ratio were synthesized *via* an environmental friendly, economical and green synthetic strategy.¹²³ They were then subjected to antimicrobial activity evaluation against pathogenic microorganisms which include Gram-negative bacteria (*Escherichia coli* and *Salmonella*) as well as Gram-positive bacteria (*Marsa*, *Listeria*, *Staphylococcus aureus*, *Bacillus subtilis*) and also a pathogenic fungal species, *Candidia*. The results revealed that the systems displayed inhibition against the tested pathogens.

M. Elango *et al.* carried out a systematic study on the development, characterization and antimicrobial potency investigation of polyindole stabilized Ag-Co₃O₄ nanocomposites.¹²⁴ The crystallinity was found to be increasing, with an increase in Ag content. XRD results show that the polyindole acts as a reducing as well as a stabilising agent for AgNO₃ to develop polyindole/Ag-Co₃O₄ systems. Porous structure of the polyindole, as evident from TEM images (Fig. 10), makes effective incorporation of Ag and Co₃O₄ into it.

The developed polyindole/Ag-Co₃O₄ nanocomposites were subjected to antibacterial and antifungal activity by disk diffusion method. Bacterial species selected for the studies were *B. subtilis*, *S. aureus*, *S. pneumoniae*, *E. coli*, *P. vulgaris* and *K. pneumoniae*. The fungal species used were *A. fumigates*, *A. flavus*, *A. niger*, *C. albicans*, *A. terreus* and *C. tropicalis*. Ciprofloxacin and amphotericin-B were used as the reference antibacterial and antifungal agents and a comparison of antimicrobial




Fig. 10 TEM images of polyindole at different magnifications. Reprinted with permission from ref. 124; copyright © Elsevier.

responses of the nanocomposites with these standards were made. It was a notable observation that the antimicrobial efficiency did not increase with an increase in Ag content.

Fig. 11 and 12 shows the comparative antibacterial and antifungal activity of the polyindole/Ag-Co₃O₄ systems, respectively. The polyindole/Ag-Co₃O₄ nanocomposites exhibited better antibacterial activity than its constituents. The antibacterial activity is due to the interaction between the nanocomposite surface and bacterial cell wall. As the size of the composite particles remains smaller, they can simply pierce the cell wall of bacteria, causing severe toxicity to the bacterial species.⁹⁹ Conducting polymers have shown to cause cell death of bacteria, owing to their excellent antibacterial properties. The nanocomposites may have the sensitivity towards bacterial and fungal cell wall structures, which contribute to their antibacterial activities.¹²⁵⁻¹²⁷ All the developed systems exhibited good




Fig. 11 Comparative antibacterial activity of the systems against the pathogens by well diffusion method. Reprinted with permission from ref. 124; copyright © Elsevier.






Fig. 12 Comparative antifungal activity of the systems against the pathogens by well diffusion method. Reprinted with permission from ref. 124; copyright © Elsevier.

antibacterial activity against the selected pathogenic microorganisms. The results facilitate the need for further research in order to explore the applications of polyindole/Ag–Co₃PO₄ nanocomposites as efficient biomedical agents.

Solubility product (K_{sp}) of Ag₃PO₄ is 1.4×10^{-16} and solubility is 0.02 g per litre at 25 °C, is partially soluble in water. Hence, it can slowly release Ag⁺ as an antibacterial agent.¹²⁸ Simple solution-based precipitation methods may be employed for the controlled synthesis of Ag₃PO₄ nano-crystals, having good antibacterial properties.¹²⁹ Their antibacterial activity depends upon the size and smaller crystals exhibit better antibacterial activity, owing to high specific surface areas. Upon irradiating with visible light, the antibacterial properties of Ag₃PO₄ could be greatly enhanced even more than commercial streptomycin.^{130,131}

A latest study has been devoted for the evaluation of antibacterial, anti-cancerous and anti-inflammatory properties of bioactive Ag₃PO₄/polyindole nanocomposites. Ag₃PO₄ nano-crystals were grown *in situ* inside polyindole matrix to fabricate bioactive Ag₃PO₄/polyindole nanocomposites.¹³² XRD, SEM, TEM, EDX and Diffused Reflectance Spectroscopy techniques were used for the characterization of the synthesized samples. The antibacterial, anticancer and anti-inflammatory activity assays proved their outstanding ability to act as a potential biomedical agent. It is notable that even polyindole alone showed antibacterial properties for long time than Ag₃PO₄.

The intracellular ROS generation accounts for the long-standing antibacterial activity of the nanocomposites. When the composition of the polyindole was 50% of Ag₃PO₄, the intracellular ROS generation was greater, for a long time. Minimum inhibitory concentration (MIC) of Ag₃PO₄/polyindole has been observed to be equivalent to those of some metallic oxide nanoparticles.^{133,134} It was found that the nanocomposites show inhibition property against the bacterial stains, while virgin polyindole doesn't show any activity at all, this concentration range. This may be owing to the synergistic effect of the




Fig. 13 Optical density versus time plot of Ag₃PO₄/polyindole nanocomposites. Reprinted with permission from ref. 132; copyright © Royal Society of Chemistry.

partners. Optical density of *E. coli* with virgin polyindole and Ag₃PO₄/polyindole nanocomposites was found to follow a similar pattern to that of the control, with lower optical density showing the suppression of bacterial growth and the nanocomposites considerably suppressed *E. coli* to larger level than the virgin polyindole (Fig. 13).

Furthermore, Ag₃PO₄ nanocomposites displayed anticancer activity with little toxicity towards other healthy cells. Therefore, more and more research programs have to be carried out to unveil their potential medical applications.

2.2.2. Polyindole/graphene nanocomposites. Graphene and its derivatives could act as potential antimicrobial agents.¹³⁵ Their antimicrobial activity is attributed to the oxidative mechanism which has direct relation with the higher defect density. Their interactions with living cells mainly depend on factors such as degree of hydrophilicity, purity, level of functionalization, lateral size and layer number.^{136,137} However, the biocompatibility studies of graphene and its derivatives show some controversial reports.¹³⁸ They found to exhibit potential cytotoxic and genotoxic effects.¹³⁹ By incorporating graphene and its derivative nanoparticles into biocompatible polymer matrices, their cytotoxic effects can be minimized. Fig. 14 shows a schematic representation of possibility of functionalisation of graphene, for the development of antibacterial materials.¹⁴⁰

A systematic investigation has been carried out for the *in vitro* and *in vivo* antimicrobial activity evaluation by using polyindole/graphene nanocomposites with methicillin resistant *Staphylococcus aureus* (SA) pathogen. The π - π interaction between the graphene and polyindole dramatically improved the dispersion of graphene in the polyindole matrix. The antibacterial potency of freshly prepared graphene@polyindole nanocomposites with resistant SA isolates have been evaluated.⁸⁷ The standard antibiotic used was vancomycin. The interaction of graphene@polyindole nanocomposite with bacterial cell wall caused its disintegration, which was clearly






Fig. 14 Schematic representation of possibility of functionalisation of graphene, for the development of antibacterial materials. Reprinted with permission from ref. 140; copyright © MDPI.

understood from the electron microscopic studies. Significantly, the graphene@polyindole found to exhibit minimal toxicity to the mammalian cells and hence can effectively eradicate the MRSA strain with appreciable biocompatibility.

The evaluation of the mechanism of antibacterial property showed that firstly, the graphene@polyindole stick to the bacterial surface, and then it creates an irreversible interruption on the layer of the membrane of the bacteria. After that it eventually penetrated into the cells, and effectively hindered the

activity of proteins, leads to bacterial apoptosis *in vitro*. Furthermore, the skin infection mediated by *S. aureus* in BALB/C mice was effectively treated with the synthesized graphene@polyindole nanocomposites. Fig. 15(A) shows the SEM micrographs of the bacteria treated with graphene@polyindole nanocomposites. In the case of untreated samples, the morphology was found to be spherical with smooth cell surfaces. The nanocomposite treated bacteria possesses wrinkled morphology with rough surfaces. Exposure of the bacteria to graphene@polyindole nanocomposites leads to cell lysis followed by the release of cellular components. Fig. 15(B) represent the TEM images indicating the interaction of the nanocomposites with bacterial strains.

Polyindole-graphene synergy has been further confirmed from Raman spectroscopy as indicated by Fig. 16.

Presence of more sp³ carbon atoms, owing to the interaction between polyindole and graphene has been revealed from the intensity ratio of graphene and graphene polymer nanocomposites (Fig. 16). The D band to G band ratio varies from 1.26 to 1.36 for graphene and graphene@polyindole nanocomposites respectively.

The antibacterial potency of the systems, evaluated by agar diffusion assay has been shown as Fig. 17(A). Fluorescence microscopic techniques have been employed to evaluate the live-dead assay, against MRSA stains and represented as Fig. 17(B). Green fluorescence has been observed for control groups, while the samples treated for 3 hours appears to be red in colour, owing to the dye binding with bacterial DNA. The study showed that the nanocomposite is very effective for inhibition of the *S. aureus*-facilitated RBCs lysis. The work




Fig. 15 (A) SEM micrographs of the bacteria treated with graphene@polyindole nanocomposites. (B) TEM images indicating the interaction of the nanocomposites with bacterial strains. Reprinted with permission from ref. 87; copyright © American Chemical Society.






Fig. 16 Raman spectrum of polyindole and graphene@polyindole nanocomposites. Reprinted with permission from ref. 87; copyright ©American Chemical Society.

highlights the possibilities of future research for the development of a biocompatible and efficient biomedical agent against methicillin resistant *Staphylococcus aureus* (SA) pathogen.

2.2.3. Polyindole/ZrO₂ nanocomposites. Zirconia nanoparticles and mixed ligand complexes of zirconium were

evaluated for their antibacterial efficiency against bacterial strains – *E. coli*, *S. aureus* and fungal strain – *A. niger*.¹⁴¹ It was a noteworthy observation that ZrO₂ nanoparticles and Zr(IV) complexes exhibited crystal plane-dependent interaction with the micro-organisms.¹⁴¹ The study could not explain how the killing capacity of these nanoparticles is related their active surface area. They could provide an estimation of crystal plane-dependent bacterial activity of nano ZrO₂ and their mixed ligand complexes.

Another group of researchers assessed nano zirconia for their antimicrobial activity *via* well disc diffusion method.¹⁴² *B. subtilis* and *S. aureus* (Gram positive) and *E. coli* and *P. aeruginosa* (Gram negative) were selected as reference bacterial strains. Since *P. aeruginosa* possess a negatively charged cell surface, nano zirconia shows an efficient inhibitory action at higher concentrations. The *in vitro* and *in vivo* experiments reveal the possibilities of exploiting the biomedical applications of ZrO₂ nanoparticles.

S. Anandhi *et al.* synthesized polyindole/ZrO₂ nanocomposites, by using mixing solution method.¹⁴³ SEM analysis was used to understand the morphology of the synthesized polyindole, nano ZrO₂ and polyindole/ZrO₂ nanocomposites. FTIR, UV-Visible and NMR techniques have been employed for the structural confirmation of the synthesized nanocomposites. The degree of crystallinity and crystalline sizes were determined




Fig. 17 (A) Zone of inhibition against MRSA strains as a measure of anti-microbial activity. (B) The images of fluorescence of MRSA ATCC BAA-1708 were taken by a microscope after treating the cells using different graphene@polyindole formulations. Reprinted with permission from ref. 87; copyright ©American Chemical Society.




Table 6 Antibacterial activity of polyindole/ZrO₂ systems. Reprinted with permission from ref. 143; copyright © Elsevier

Microbes	Gram staining	Inhibition zone (mm)			Antibiotic (1 mg mL ⁻¹)
		Concentration of the samples (1 mg mL ⁻¹)			
<i>Staphylococcus aureus</i>	Gram positive	20	13	10	35
<i>Bacillus subtilis</i>		10	8	8	20
<i>E. coli</i>	Gram negative	15	10	9	26
<i>Salmonella typhi</i>		13	10	8	30
<i>Pseudomonas aeruginosa</i>		15	10	7	30

from XRD analysis. The thermal stability of the synthesized composites were analysed from TGA and DSC studies. EDAX technique was used to demonstrate elemental analysis and chemical characterization. The antibacterial activity of the synthesized nanocomposites were carried out on five microorganisms – *Staphylococcus aureus*, *Bacillus subtilis*, *Pseudomonas aeruginosa*, *Salmonella typhi* and *E. coli*. Table 6 presents the antibacterial results of the polyindole/ZrO₂ systems, and zone of inhibition have been represented as Fig. 18.

The polyindole/ZrO₂ systems were also subjected to antifungal activity studies against pathogenic fungal strains –

**Fig. 18** Antibacterial activity of polyindole/ZrO₂ systems against selected bacterial strains as a measurement of zone of inhibition. Reprinted with permission from ref. 143; copyright © Elsevier.**Table 7** Antifungal activity of polyindole/ZrO₂ systems. Reprinted with permission from ref. 143; copyright © Elsevier

Microbes	Zone of inhibition (mm)			Antibiotic (1 mg mL ⁻¹)
	Sample concentration (1 mg mL ⁻¹)			
	1000	750	500	
<i>Candida albicans</i>	16	15	14	17
<i>Penicillium chrysogenum</i>	11	10	8	18

Candida albicans and *Penicillium chrysogenum*. The results were compared with the standard antibiotic – amphotericin-B. The synthesized polyindole/ZrO₂ nanocomposites displayed excellent antifungal properties. Table 7 shows the antifungal data of the systems, and zone of inhibition have been represented as Fig. 19.

2.2.4. Polyindole/TiO₂ nanocomposites. The enhanced antimicrobial activity and biocompatibility of nano-TiO₂ coatings were comprehensively explored.^{144,145} Unique nano-TiO₂ coatings on Ti substrates, introduced *via* temperature-controlled atomic layer deposition (ALD), displayed excellent activity against *Staphylococcus aureus*, *Escherichia coli* and methicillin-resistant *Staphylococcus aureus*.

A systematic investigation was conducted on the development and antibacterial activity evaluation of polyindole/TiO₂ nanocomposites.¹⁴⁶ They employed ultrasound condition by aqueous *in situ* polymerization method. A representation of the synthesis strategy has been shown as Fig. 20. FTIR, UV-visible, XRD, TGA and SEM techniques were used for the structural characterization of the synthesized nanocomposite samples.

The XRD pattern indicated that TiO₂ is in the anatase form. A significant antibacterial activity could be observed for the nanocomposite samples against *B. subtilis* and *S. aureus* (Gram-positive). However, a moderate activity was observed against *E. coli* (Gram-negative) whereas no activity was observed against *S. typhi*. The zone of inhibition has been indicated in Fig. 21.

It was proposed that the antibacterial activity of the polyindole/TiO₂ nanocomposite materials is attributed to their ability to inhibit nucleic acids, thiol groups and essential enzymes present on the bacterial cell membranes. Hence, these materials act as a promising candidate and their use could be a novel approach to fight drug-resistant bacterial infections.

2.2.5. Polyindole/nickel-zinc oxide nanocomposites. The antifungal properties of polyindole based nickel-zinc oxide (PIN/Ni-ZnO) nanocomposites was reported recently.¹⁴⁷ The well-known co-precipitation method, by using a capping agent was selected for the preparation of nickel-zinc oxide nanocomposites. The chemical oxidation method has been employed for the preparation of PIN/Ni-ZnO nanocomposites. The antifungal investigation of PIN/Ni-ZnO nanocomposite and its counterparts have been carried out by using test fungi species *Penicillium chrysogenum*, showed that the nanocomposite has an antifungal activity of 1 cm, the nickel-zinc






Fig. 19 Antifungal activity of the composite material against selected bacterial strains as a measurement of zone of inhibition. Reprinted with permission from ref. 143; copyright © Elsevier.

oxide component showed an activity of 0.7 cm and whereas the nickel oxide, zinc oxide and polyindole were showing no remarkable activity.

From this study, it is evident that when NiO/ZnO nanocomposite combines with polyindole matrix, there observed a higher antifungal activity than the single NiO/ZnO nanocomposites. This enhanced antimicrobial activity of the polymer nanocomposite has been due to the synergistic effect of both the polymer matrix and metal oxide nanoparticle counterparts in favour of appreciable ROS generation. From the above results, we can conclude that the synthesized polyindole/

NiO–ZnO nanocomposite could act as a potential antifungal material to fight the fungal infection caused by *Penicillium chrysogenum*.

3. Future perspectives

Polyindole based nanocomposites were observed to be a potential biomaterial against the multi-drug resistant microbes. They can be used as an alternative to antibiotics and antifungal drugs. Clinical and *in vivo* applications are largely based on the size of the released nanoparticles from the polymer nanocomposites. Hence, it necessitates the need for effective toxicological studies and investigations of the polymer nanocomposites before initiating clinical trials. Another concern is at the development of an economical as well as an ecofriendly method for the synthesis of polyindole based nanocomposite is required. However, nowadays more and more researchers are coming up with some innovative green synthetic strategies, which may give progress to the field of polyindole based nanocomposites for biomedical applications.




Fig. 20 Synthesis strategy of polyindole/TiO₂ nanocomposites. Reprinted with permission from ref. 146; copyright © Taylor and Francis Ltd.




Fig. 21 Antibacterial activity as a measure of zone of inhibition for polyindole/TiO₂ nanocomposite against (a) *Staphylococcus aureus*, (b) *Bacillus subtilis* and (c) *E. coli*. Reprinted with permission from ref. 146; copyright © Taylor and Francis Ltd.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Dr Bindu M. is thankful to KSCSTE for her Back to Lab Post-Doctoral Fellowship, Grant No 161/2021/KSCSTE. Anjitha Thadathil is grateful to CSIR for her CSIR-JRF fellowship.

References

- 1 S. Alfei and A. M. Schito, *Nanomaterials*, 2020, **10**, 2022.
- 2 J. Munguia and V. Nizet, *Trends Pharmacol. Sci.*, 2017, **38**, 473–488.
- 3 C. L. Ventola, *Pharm. Therapeut.*, 2015, **40**, 277.
- 4 N. F. Kamaruzzaman, L. P. Tan, R. H. Hamdan, S. S. Choong, W. K. Wong, A. J. Gibson, A. Chivu and M. d. F. Pina, *Int. J. Mol. Sci.*, 2019, **20**, 2747.



- 5 J. Hoque, S. Ghosh, K. Paramanandham and J. Haldar, *ACS Appl. Mater. Interfaces*, 2019, **11**, 39150–39162.
- 6 D. Olmos and J. González-Benito, *Polymers*, 2021, **13**, 613.
- 7 F. A. G. d. Silva, S. A. Vieira, S. d. A. Botton, M. M. d. Costa and H. P. d. Oliveira, *Polímeros*, 2021, **30**, 1–9.
- 8 A. J. Huh and Y. J. Kwon, *J. Controlled Release*, 2011, **156**, 128–145.
- 9 L. Wang, C. Hu and L. Shao, *Int. J. Nanomed.*, 2017, **12**, 1227.
- 10 L. C. Yun'an Qing, R. Li, G. Liu, Y. Zhang, X. Tang, J. Wang, H. Liu and Y. Qin, *Int. J. Nanomed.*, 2018, **13**, 3311.
- 11 A. A. Dayem, M. K. Hossain, S. B. Lee, K. Kim, S. K. Saha, G.-M. Yang, H. Y. Choi and S.-G. Cho, *Int. J. Mol. Sci.*, 2017, **18**, 1–21.
- 12 F. Ciccicarese, V. Raimondi, E. Sharova, M. Silic-Benussi and V. Ciminale, *Antioxidants*, 2020, **9**, 211.
- 13 A. Manke, L. Wang and Y. Rojanasakul, *BioMed Res. Int.*, 2013, **2013**, 942916.
- 14 V. T. Nguyen, V. T. Vu, T. A. Nguyen, V. K. Tran and P. Nguyen-Tri, *J. Compos. Sci.*, 2019, **3**, 61.
- 15 A. Raghunath and E. Perumal, *Int. J. Antimicrob. Agents*, 2017, **49**, 137–152.
- 16 S. V. Gudkov, D. E. Burmistrov, D. A. Serov, M. B. Rebezov, A. A. Semenova and A. B. Lisitsyn, *Front. Phys.*, 2021, **9**, 641481, DOI: 10.3389/fphy.
- 17 B. Abebe, E. A. Zereffa, A. Tadesse and H. A. Murthy, *Nanoscale Res. Lett.*, 2020, **15**, 1–19.
- 18 L. M. Anaya-Esparza, E. Montalvo-González, N. González-Silva, M. D. Méndez-Robles, R. Romero-Toledo, E. M. Yahia and A. Pérez-Larios, *Materials*, 2019, **12**, 698.
- 19 B. Yang, Y. Chen and J. Shi, *Chem. Rev.*, 2019, **119**, 4881–4985.
- 20 J. Singh, K. Vishwakarma, N. Ramawat, P. Rai, V. K. Singh, R. K. Mishra, V. Kumar, D. K. Tripathi and S. Sharma, *3 Biotech*, 2019, **9**, 1–14.
- 21 N. Sanvicens and M. P. Marco, *Trends Biotechnol.*, 2008, **26**, 425–433.
- 22 A. M. Knaapen, P. J. Borm, C. Albrecht and R. P. Schins, *Int. J. Cancer*, 2004, **109**, 799–809.
- 23 A. Nel, T. Xia, L. Mädler and N. Li, *science*, 2006, **311**, 622–627.
- 24 B. Fubini and A. Hubbard, *Free Radicals Biol. Med.*, 2003, **34**, 1507–1516.
- 25 V. J. Thannickal and B. L. Fanburg, *Am. J. Physiol.: Lung Cell. Mol. Physiol.*, 2000, **279**, L1005–L1028.
- 26 M. Valko, C. Rhodes, J. Moncol, M. Izakovic and M. Mazur, *Chem.-Biol. Interact.*, 2006, **160**, 1–40.
- 27 G. Oberdörster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J. Carter, B. Karn, W. Kreyling and D. Lai, *Part. Fibre Toxicol.*, 2005, **2**, 1–35.
- 28 P. Riley, *Int. J. Radiat. Biol.*, 1994, **65**, 27–33.
- 29 A. Abdal Dayem, M. K. Hossain, S. B. Lee, K. Kim, S. K. Saha, G.-M. Yang, H. Y. Choi and S.-G. Cho, *Int. J. Mol. Sci.*, 2017, **18**, 120.
- 30 X. Zhang, L. Wang, H. Lu, Z. Zong, Z. Chen, Y. Li, X. Luo and Y. Li, *Sci. Rep.*, 2020, **10**, 1–11.
- 31 C. Ransy, C. Vaz, A. Lombès and F. Bouillaud, *Int. J. Mol. Sci.*, 2020, **21**, 9149.
- 32 K. S. Kim, D. Lee, C. G. Song and P. M. Kang, *Nanomedicine*, 2015, **10**, 2709–2723.
- 33 Y. Wang, H. Qi, Y. Liu, C. Duan, X. Liu, T. Xia, D. Chen, H.-l. Piao and H.-X. Liu, *Theranostics*, 2021, **11**, 4839.
- 34 V. Aggarwal, H. S. Tuli, A. Varol, F. Thakral, M. B. Yerer, K. Sak, M. Varol, A. Jain, M. Khan and G. Sethi, *Biomolecules*, 2019, **9**, 735.
- 35 R. Spooner and Ö. Yilmaz, *Int. J. Mol. Sci.*, 2011, **12**, 334–352.
- 36 F. Gao, T. Shao, Y. Yu, Y. Xiong and L. Yang, *Nat. Commun.*, 2021, **12**, 1–18.
- 37 M. Herb and M. Schramm, *Antioxidants*, 2021, **10**, 313.
- 38 M. Mittal, M. R. Siddiqui, K. Tran, S. P. Reddy and A. B. Malik, *Antioxid. Redox Signaling*, 2014, **20**, 1126–1167.
- 39 X. Li, P. Fang, J. Mai, E. T. Choi, H. Wang and X.-f. Yang, *J. Hematol. Oncol.*, 2013, **6**, 1–19.
- 40 H. H. Gustafson, D. Holt-Casper, D. W. Grainger and H. Ghandehari, *Nano today*, 2015, **10**, 487–510.
- 41 R. A. Freitas Jr, *Nanomedicine*, 2005, **1**, 2–9.
- 42 L. Ge, Q. Li, M. Wang, J. Ouyang, X. Li and M. M. Xing, *Int. J. Nanomed.*, 2014, **9**, 2399.
- 43 Y. N. Slavin, J. Asnis, U. O. Häfeli and H. Bach, *J. Nanobiotechnol.*, 2017, **15**, 1–20.
- 44 C. Bankier, R. Matharu, Y. Cheong, G. Ren, E. Cloutman-Green and L. Ciric, *Sci. Rep.*, 2019, **9**, 1–8.
- 45 N. Dhull, V. Gupta and M. Tomar, *Mater. Today: Proc.*, 2019, **17**, 155–160.
- 46 Z. Qiu, B. A. G. Hammer and K. Müllen, *Prog. Polym. Sci.*, 2020, **100**, 101179.
- 47 Q. Cui, H. Yuan, X. Bao, G. Ma, M. Wu and C. Xing, *ACS Appl. Bio Mater.*, 2020, **3**, 4436.
- 48 T. F. Abelha and A. R. L. Caires, *Adv. NanoBiomed. Res.*, 2021, **1**, 2100012.
- 49 B. C. Wilson and R. A. Weersink, *Photochem. Photobiol.*, 2020, **96**, 219.
- 50 L. Liu, X. Wang, S. Zhu, C. Yao, D. Ban, R. Liu, L. Li and S. Wang, *Chem. Mater.*, 2020, **32**, 438.
- 51 S. Fu, Z. Sun, P. Huang, Y. Li and N. Hu, *Nano Mater. Sci.*, 2019, **1**, 2–30.
- 52 M. Šupová, G. S. Martynková and K. Barabaszová, *Sci. Adv. Mater.*, 2011, **3**, 1–25.
- 53 Y. Wang, G. J. Desroches and R. J. Macfarlane, *Nanoscale*, 2021, **13**, 426–443.
- 54 L. A. Savas and M. Hancer, *Appl. Clay Sci.*, 2015, **108**, 40–44.
- 55 Y. Dong, M. Argai, B. He, R. Tomovska, T. Sun and I. Martín-Fabiani, *ACS Appl. Polym. Mater.*, 2020, **2**, 626–635.
- 56 K. M. Nampoothiri, N. R. Nair and R. P. John, *Bioresour. Technol.*, 2010, **101**, 8493–8501.
- 57 F. Asghari, M. Samiei, K. Adibkia, A. Akbarzadeh and S. Davaran, *Artif. Cells, Nanomed., Biotechnol.*, 2017, **45**, 185–192.
- 58 G. K. Arbade, J. Srivastava, V. Tripathi, N. Lenka and T. U. Patro, *J. Biomater. Sci., Polym. Ed.*, 2020, **31**, 1648–1670.
- 59 R. A. Green, S. Baek, L. A. Poole-Warren and P. J. Martens, *Sci. Technol. Adv. Mater.*, 2010, **11**, 014107.



- 60 J. G. Ibanez, M. E. Rincón, S. Gutierrez-Granados, M. h. Chahma, O. A. Jaramillo-Quintero and B. A. Frontana-Urbe, *Chem. Rev.*, 2018, **118**, 4731–4816.
- 61 T. Nezakati, A. Seifalian, A. Tan and A. M. Seifalian, *Chem. Rev.*, 2018, **118**, 6766–6843.
- 62 K. Namsheer and C. S. Rout, *RSC Adv.*, 2021, **11**, 5659–5697.
- 63 A. Konwar, S. Kalita, J. Kotoky and D. Chowdhury, *ACS Appl. Mater. Interfaces*, 2016, **8**, 20625–20634.
- 64 A. Sanmugam, D. Vikraman, H. J. Park and H.-S. Kim, *Nanomaterials*, 2017, **7**, 363.
- 65 W. Xu, W. Xie, X. Huang, X. Chen, N. Huang, X. Wang and J. Liu, *Food Chem.*, 2017, **221**, 267–277.
- 66 Y.-C. Cao, W. Wei, J. Liu, Q. You, F. Liu, Q. Lan, C. Zhang, C. Liu and J. Zhao, *Int. J. Polym. Sci.*, 2015, **2015**, 1–7.
- 67 R. Surudžić, A. Janković, N. Bibić, M. Vukašinović-Sekulić, A. Perić-Grujić, V. Mišković-Stanković, S. J. Park and K. Y. Rhee, *Composites, Part B*, 2016, **85**, 102–112.
- 68 Y. Huang, T. Wang, X. Zhao, X. Wang, L. Zhou, Y. Yang, F. Liao and Y. Ju, *J. Chem. Technol. Biotechnol.*, 2015, **90**, 1677–1684.
- 69 H. Mahdavi, O. Rahmani and A. R. Shahverdi, *J. Iran. Chem. Soc.*, 2017, **14**, 37–46.
- 70 A. Salabat, F. Mirhoseini, M. Mahdih and H. Saydi, *New J. Chem.*, 2015, **39**, 4109–4114.
- 71 M. Maruthapandi, A. Saravanan, J. H. Luong and A. Gedanken, *Polymers*, 2020, **12**, 1286.
- 72 J. Upadhyay, A. Kumar, B. Gogoi and A. Buragohain, *Mater. Sci. Eng., C*, 2015, **54**, 8–13.
- 73 P. Boomi, H. G. Prabu and J. Mathiyarasu, *Eur. J. Med. Chem.*, 2014, **72**, 18–25.
- 74 M. D. Adhikari, S. Goswami, B. R. Panda, A. Chattopadhyay and A. Ramesh, *Adv. Healthcare Mater.*, 2013, **2**, 599–606.
- 75 U. Bogdanovic, V. Vodnik, M. Mitric, S. Dimitrijevic, S. D. Skapin, V. Zunic, M. Budimir and M. Stojkovic, *ACS Appl. Mater. Interfaces*, 2015, **7**, 1955–1966.
- 76 R. Hassanien, M. Al-Hinai, S. A. Farha Al-Said, R. Little, L. Siller, N. G. Wright, A. Houlton and B. R. Horrocks, *ACS Nano*, 2010, **4**, 2149–2159.
- 77 H. Mudila, P. Prasher, M. Kumar, A. Kumar, M. Zaidi and A. Kumar, *Mater. Renew. Sustain. Energy*, 2019, **8**, 1–19.
- 78 I. Marriam, W. Yuanhao and M. Tebyetekerwa, *Energy Storage Mater.*, 2020, 336–359.
- 79 J. Li, Q. Guo, Y. Lu and G. Nie, *Eur. Polym. J.*, 2019, **113**, 29–35.
- 80 K. Phasuksom, W. Prissanaroon-Ouajai and A. Sirivat, *Sens. Actuators, B*, 2018, **262**, 1013–1023.
- 81 M.-T. Nguyen, B. Mecheri, A. Iannaci, A. D'Epifanio and S. Licoccia, *Electrochim. Acta*, 2016, **190**, 388–395.
- 82 M. Mobin, F. Ansar, M. Shoeb, M. Parveen and J. Aslam, *Nano Sel.*, 2021, **2**, 293–302.
- 83 P. Chhattise, K. Handore, A. Horne, K. Mohite, A. Chaskar, S. Dallavalle and V. Chabukswar, *J. Chem. Sci.*, 2016, **128**, 467–475.
- 84 Q. Zhou, D. Zhu, X. Ma, J. Xu, W. Zhou and F. Zhao, *RSC Adv.*, 2016, **6**, 29840–29847.
- 85 H. L. Youmans, J. B. Rush and V. H. Brown, *J. Heterocycl. Chem.*, 1976, **13**, 949–953.
- 86 G. Tourillon and F. Garnier, *J. Electroanal. Chem. Interfacial Electrochem.*, 1982, **135**, 173–178.
- 87 M. Shoeb, M. Mobin, M. A. Rauf, M. Owais and A. H. Naqvi, *ACS Omega*, 2018, **3**, 9431–9440.
- 88 R. B. Choudhary, S. Ansari and B. Purty, *J. Energy Storage*, 2020, **29**, 101302.
- 89 W. Zhou and J. Xu, *Polym. Rev.*, 2017, **57**, 248–275.
- 90 P. Pandey and R. Prakash, *J. Electrochem. Soc.*, 1998, **145**, 999.
- 91 T. Puzyn, B. Rasulev, A. Gajewicz, X. Hu, T. P. Dasari, A. Michalkova, H.-M. Hwang, A. Toropov, D. Leszczynska and J. Leszczynski, *Nat. Nanotechnol.*, 2011, **6**, 175–178.
- 92 A. Srivastava, P. Singh, R. Kumar, S. K. Verma and R. N. Kharwar, *Polym. Int.*, 2013, **62**, 210–218.
- 93 P. Dallas, V. K. Sharma and R. Zboril, *Adv. Colloid Interface Sci.*, 2011, **166**, 119–135.
- 94 V. K. H. Bui, D. Park and Y.-C. Lee, *Polymers*, 2017, **9**, 21.
- 95 Z. Ding, M. Ding, C. Gao, C. Boyer and W. Zhang, *Macromolecules*, 2017, **50**, 7593–7602.
- 96 H. Gong, K. Zhang, C. Dicko, L. Bülow and L. Ye, *ACS Appl. Nano Mater.*, 2019, **2**, 1655–1663.
- 97 E. Said-Galiev, A. Gamzazade, T. Grigor'ev, A. Khokhlov, N. Bakuleva, I. Lyutova, E. Shtykova, K. Dembo and V. Volkov, *Nanotechnol. Russ.*, 2011, **6**, 341–352.
- 98 T. C. Dakal, A. Kumar, R. S. Majumdar and V. Yadav, *Front. Microbiol.*, 2016, **7**, 1831.
- 99 S. Prabhu and E. K. Poulouse, *Int. Nano Lett.*, 2012, **2**, 1–10.
- 100 S. Liao, Y. Zhang, X. Pan, F. Zhu, C. Jiang, Q. Liu, Z. Cheng, G. Dai, G. Wu and L. Wang, *Int. J. Nanomed.*, 2019, **14**, 1469.
- 101 A. B. Smetana, K. J. Klabunde, G. R. Marchin and C. M. Sorensen, *Langmuir*, 2008, **24**, 7457–7464.
- 102 R. Kumar, S. K. Shrivastava and A. Chakraborti, *Am. J. Biomed. Sci.*, 2010, **2**, 202–208.
- 103 A. Ashnagar, N. G. Naseri and S. Alboghobesh, *Biosci., Biotechnol. Res. Asia*, 2007, **4**, 65–70.
- 104 K. Mallikarjuna, G. Narasimha, G. Dillip, B. Praveen, B. Shreedhar, C. S. Lakshmi, B. Reddy and B. D. P. Raju, *Dig. J. Nanomater. Biostructures*, 2011, **6**, 181–186.
- 105 L. He, Y. Liu, A. Mustapha and M. Lin, *Microbiol. Res.*, 2011, **166**, 207–215.
- 106 J. W. Rasmussen, E. Martinez, P. Louka and D. G. Wingett, *Expert Opin. Drug Delivery*, 2010, **7**, 1063–1077.
- 107 R. Singh, S. Cheng and S. Singh, *3 Biotech*, 2020, **10**, 1–13.
- 108 K. S. Siddiqi, A. ur Rahman and A. Husen, *Nanoscale Res. Lett.*, 2018, **13**, 1–13.
- 109 I. Matai, A. Sachdev, P. Dubey, S. U. Kumar, B. Bhushan and P. Gopinath, *Colloids Surf., B*, 2014, **115**, 359–367.
- 110 M. Elango, M. Deepa, R. Subramanian and A. M. Musthafa, *J. Alloys Compd.*, 2017, **696**, 391–401.
- 111 G. Grass, C. Rensing and M. Solioz, *Appl. Environ. Microbiol.*, 2011, **77**, 1541–1547.
- 112 J. Ren, W. Wang, S. Sun, L. Zhang, L. Wang and J. Chang, *Ind. Eng. Chem. Res.*, 2011, **50**, 10366–10369.
- 113 N. Ghasemi, F. Jamali-Sheini and R. Zekavati, *Mater. Lett.*, 2017, **196**, 78–82.
- 114 M. Elango, M. Deepa, R. Subramanian and A. Mohamed Musthafa, *Polym.-Plast. Technol. Eng.*, 2018, **57**, 1440–1451.



Review

- 115 M. Cabuk, Y. Alan and H. I. Unal, *Carbohydr. Polym.*, 2017, **161**, 71–81.
- 116 M. Qi, W. Li, X. Zheng, X. Li, Y. Sun, Y. Wang, C. Li and L. Wang, *Front. Mater.*, 2020, **7**, 213.
- 117 A. B. Shcherbakov, V. V. Reukov, A. V. Yakimansky, E. L. Krasnopeeva, O. S. Ivanova, A. L. Popov and V. K. Ivanov, *Polymers*, 2021, **13**, 924.
- 118 F. Mohammad, T. Arfin and H. A. Al-Lohedan, *J. Ind. Eng. Chem.*, 2017, **45**, 33–43.
- 119 K. Negi, A. Umar, M. Chauhan and M. S. Akhtar, *Ceram. Int.*, 2019, **45**, 20509–20517.
- 120 M. Elango, M. Deepa, R. Subramanian and G. Saraswathy, *Mater. Today: Proc.*, 2020, **26**, 3544–3551.
- 121 K. Zheng, M. I. Setyawati, D. T. Leong and J. Xie, *Coord. Chem. Rev.*, 2018, **357**, 1–17.
- 122 M. Hafeez, R. Shaheen, B. Akram, S. Haq, S. Mahsud, S. Ali and R. T. Khan, *Mater. Res. Express*, 2020, **7**, 025019.
- 123 H. A. Hassanin, A. Taha and E. Afkar, *Ceram. Int.*, 2021, **47**, 3099–3107.
- 124 M. Elango, M. Deepa, R. Subramanian and G. Saraswathy, *Mater. Chem. Phys.*, 2018, **216**, 305–315.
- 125 S. Jadoun, U. Riaz and V. Budhiraja, *Med. Devices Sens.*, 2021, **4**, e10141.
- 126 S. S. Nair, S. K. Mishra and D. Kumar, *Polym. Adv. Technol.*, 2019, **30**, 2932–2953.
- 127 X. Chen and J. Li, *Mater. Chem. Front.*, 2020, **4**, 750–774.
- 128 I. X. Yin, J. Zhang, I. S. Zhao, M. L. Mei, Q. Li and C. H. Chu, *Int. J. Nanomed.*, 2020, **15**, 2555.
- 129 A. Wu, C. Tian, W. Chang, Y. Hong, Q. Zhang, Y. Qu and H. Fu, *Mater. Res. Bull.*, 2013, **48**, 3043–3048.
- 130 Y. Seo, B.-E. Yeo, Y.-S. Cho, H. Park, C. Kwon and Y.-D. Huh, *Mater. Lett.*, 2017, **197**, 146–149.
- 131 U. Sulaeman, F. Febiyanto, S. Yin and T. Sato, *Catal. Commun.*, 2016, **85**, 22–25.
- 132 S. Podder, S. Paul, P. Basak, B. Xie, N. J. Fullwood, S. J. Baldock, Y. Yang, J. G. Hardy and C. K. Ghosh, *RSC Adv.*, 2020, **10**, 11060–11073.
- 133 R. Y. Pelgrift and A. J. Friedman, *Adv. Drug Delivery Rev.*, 2013, **65**, 1803–1815.
- 134 A. Samanta, S. Podder, C. K. Ghosh, M. Bhattacharya, J. Ghosh, A. K. Mallik, A. Dey and A. K. Mukhopadhyay, *J. Mech. Behav. Biomed. Mater.*, 2017, **72**, 110–128.
- 135 L. Shi, J. Chen, L. Teng, L. Wang, G. Zhu, S. Liu, Z. Luo, X. Shi, Y. Wang and L. Ren, *Small*, 2016, **12**, 4165–4184.
- 136 C. Liao, Y. Li and S. C. Tjong, *Int. J. Mol. Sci.*, 2018, **19**, 3564.
- 137 S. Syama and P. Mohanan, *Int. J. Biol. Macromol.*, 2016, **86**, 546–555.
- 138 O. Erol, I. Uyan, M. Hatip, C. Yilmaz, A. B. Tekinay and M. O. Guler, *Nanomedicine*, 2018, **14**, 2433–2454.
- 139 L. Ou, B. Song, H. Liang, J. Liu, X. Feng, B. Deng, T. Sun and L. Shao, *Part. Fibre Toxicol.*, 2016, **13**, 1–24.
- 140 P. Kumar, P. Huo, R. Zhang and B. Liu, *Nanomaterials*, 2019, **9**, 737.
- 141 M. Khan, M. R. Shaik, S. T. Khan, S. F. Adil, M. Kuniyil, M. Khan, A. A. Al-Warthan, M. R. H. Siddiqui and M. Nawaz Tahir, *ACS Omega*, 2020, **5**, 1987–1996.
- 142 J. B. Fathima, A. Pugazhendhi and R. Venis, *Microb. Pathog.*, 2017, **110**, 245–251.
- 143 S. Anandhi, M. L. Edward and V. Jaisankar, *Mater. Today: Proc.*, 2021, **40**, S93–S101.
- 144 L. Liu, R. Bhatia and T. J. Webster, *Int. J. Nanomed.*, 2017, **12**, 8711.
- 145 S. Jafari, B. Mahyad, H. Hashemzadeh, S. Janfaza, T. Gholikhani and L. Tayebi, *Int. J. Nanomed.*, 2020, **15**, 3447.
- 146 K. Handore, D. Walunj, P. Chhattise, A. Chabukswar, K. Mohite, S. Dallavalle, B. Bharat and V. Chabukswar, *Polym.-Plast. Technol. Eng.*, 2017, **56**, 1259–1266.
- 147 D. Devadathan and R. Raveendran, *Int. J. Chem. Eng. Appl.*, 2014, **5**, 240.

